Surgery Partners vs Universal Health Services
SGRY and UHS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SGRY and UHS compare
Universal Health Services is the larger company, worth 3.2 times as much as Surgery Partners ($11.3B against $3.5B).
Universal Health Services grew revenue faster over the last twelve months (10.0% versus 4.0% for Surgery Partners).
Universal Health Services keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −2.6% at Surgery Partners.
Universal Health Services pays a dividend yielding 0.42%; Surgery Partners does not pay one.
Universal Health Services scores higher on the StockData Score (22 against 5 for Surgery Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SGRY | UHS |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $11.3B |
| Share price | $26.85 | $191.98 |
| Change, 1 year | 75.7% | −14.7% |
| Change, 5 years | −38.6% | 54.4% |
| Beta (5Y) | 1.06 | −0.03 |
| Employees | 16K | 102K |
| StockData Score | ||
| Total score | 5 | 22 (better) |
| Valuation score | 1 | 6 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 7.8× |
| P/S | 1.0× | 0.6× (better) |
| P/B | 2.1× | 1.5× (better) |
| EV/EBITDA | 15.1× | 6.0× (better) |
| P/FCF | 18.7× | 13.4× (better) |
| PEG | – | 0.22 |
| FCF yield | 5.3% | 7.5% (better) |
| Fair value | $24.21 | $357.53 |
| Margin of safety | −10.9% | 46.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 4.0% | 10.0% (better) |
| Revenue growth, 5Y average | 12.2% (better) | 8.5% |
| Net income growth (TTM) | – | 21.0% |
| EPS growth (TTM) | – | 29.3% |
| EPS growth, 5Y average | – | 16.0% |
| Profitability | ||
| Operating margin | 11.4% (better) | 11.4% |
| Net margin | −2.6% | 8.4% (better) |
| FCF margin | 5.6% (better) | 4.7% |
| Return on equity | −5.2% | 21.0% (better) |
| Return on invested capital | 5.9% | 13.3% (better) |
| Financial health | ||
| Debt / equity | 2.25 | 0.65 (better) |
| Net debt / EBITDA | 6.30 | 1.75 (better) |
| Interest coverage | – | 13.1× |
| Current ratio | 1.95 (better) | 1.12 |
| Altman Z-score | 0.93 | 2.40 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.42% |
| Payout ratio | – | 3.2% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 9.3% |
| Shareholder yield | 0.00% | 9.8% (better) |
| Ownership | ||
| Held by institutions | 121% | 96.4% |
| Held by insiders | 85.9% | 17.2% |
| Insider net buying, 12 months | −$979K | −$128K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 48.6% | 5.2% |
Go deeper
- SGRY stock overview
- SGRY income statement
- SGRY valuation and score
- UHS stock overview
- UHS income statement
- UHS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.